Valeant Pharmaceuticals International announced Wednesday its proposed buyout of Solta medical has earned regulatory clearance due to the expiration of the HSR waiting period, according to a press release.
The merger was first announced last month as Valeant revealed a purchase price of $250 million. The transaction included a share price of $2.92, the release said.
Full Content: RTT News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Malaysia Grants Licenses to WeChat and TikTok Under New Social Media Law
Jan 2, 2025 by
CPI
Axinn Announces Promotions of Antitrust Experts
Jan 2, 2025 by
CPI
Federal Competition Office to Scrutinize High Electricity Prices in Germany
Jan 2, 2025 by
CPI
Mexican Lawmakers Advance Controversial Plan to Dissolve Independent Oversight Bodies
Jan 2, 2025 by
CPI
Motorola Accuses UK of Antitrust Breach Over Terminated Emergency Services Contract
Jan 2, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand